THOR Laser Logo


THOR Newsletter
PBM Research, Training & Conferences

  • Literature Watch for May: 27 PBM Therapy papers published in January 2018
  • LLLT is dead: Long live PBM
  • Training dates and cities : USA, UK, Canada, Australia and New Zealand
  • Conferences: France and USA
  • Privacy Policy: An update
  • The Bottom Line: Major steps forward for PBM treatment of Oral Mucositis

Literature Watch

27 Photobiomodulation therapy papers published in January 2018. Highlights include: Treatment 6h before + immediately before exercise best for reducing muscle fatigue - Review of pre-clinical data for dementia, Parkinson's, stroke, trauma and depression - Improved bacteriological, cytological and clinical benefits after root planing (RCT) - Improved wound healing of skin graft donor site (RCT) - Systematic review of RCTs on LED PBM therapy in dermatology - NSAIDs vs PBM Therapy post root canal (RCT) - ESWT vs PBM Therapy for Plantar Fasciitis (RCT) - Effect of PBM on cerebral hemodynamics and metabolism are not thermal

Click here for more

LLLT is dead, long live PBM

In case you missed the memo, Low Level Laser Therapy (LLLT) has been retired in favour of Photobiomodulation (PBM). Click here to learn more

THOR Training dates and cities:

We study PBM Therapy relentlessly (had you noticed?). We use our knowledge to develop our training, treatments and products. Come see what we have learnt since your last training. Now available with Continuing Medical/Dental Education credits.

  • What is the difference between the anti-inflammatory effects of PBM Therapy, the healing and the analgesic mechanisms?
  • Have you thought about treating lymphatics?
  • Are you de-activating trigger points (and how does that work!)?
  • How much PBM Therapy is enough, how much is too much?
  • Joules or J/cm2 - which is the right way to express dose and how is it calculated?
  • Lasers or LEDs, red or infrared wavelengths, high or low power density, pulsed or continuous?
  • Treatment times and treatment intervals and when to expect a result.
  • Safety, contraindications, adverse effects, regulations and reimbursement

It seems like a lot to learn in one day but we use videos, cartoons and a 50 page illustrated book to help you so very little note-taking is required. A certificate of attendance is provided.

Discounts for groups, repeat attendees and early registration.

Date Location Country
Sat, 8 Sep 2018 London UK
Thu, 13 Sep 2018 Melbourne Australia
Tue, 18 Sep 2018 Auckland New Zealand
Wed, 26 Sep 2018 Manchester UK
Wed, 10 Oct 2018 New York NY USA
Tue, 13 Nov 2018 Atlanta GA USA
Wed, 14 Nov 2018 Houston TX USA
Fri, 16 Nov 2018 Vancouver BC Canada
Sat, 17 Nov 2018 Seattle WA USA
Mon, 10 Dec 2018 San Diego CA USA
Wed, 12 Dec 2018 Las Vegas NV USA

Click here for more

International Conferences

Date Description Location
October 3-6, 2018 WALT 2018 Congress Nice, France
February 2-7, 2019 SPIE International society for optics and photonics San Francisco CA, USA

Click here for more


An update to our privacy policy

Like many companies, we are updating our privacy policy in light of GDPR. You can see our updated privacy policy here. If you wish to manage your email subscription preferences, please follow the links at the bottom of this email.

The Bottom Line — the major steps forward for PBM treatment of Oral Mucositis

After three presentations and much correspondence over a 5 year period we have a recommendation guideline from the National Institute of Health and Care Excellence (NICE) — LLLT for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. This means the NHS can start using our treatment on cancer patients to reduce oral mucositis.

This was a relay race with generations of researchers picking up the baton from earlier pioneers. It was Rene-Jean Bensadoun who twisted my arm to get me to take an interest in the treatment of OM at the 2010 WALT conference in Bergen, Norway. The first OM laser study I know of was in Ciais et al 1992. The first Randomised study was Cowen et al 1997. Rene-Jean Bensadoun published the first multicenter phase III study in 1999 and now there are 170 papers referencing the treatment of oral mucositis with PBM 32 of which  are randomised controlled clinical trials.

The Multinational Association of Supportive Care in Cancer (MASCC) guidelines 2013 recommend PBM for HSCT patients, Blue Cross Blue Shield reimburse for OM in the United States, and now NICE recommend it's use in the UK. Last year Antunes et al 2017 published a study showing statistically significant improved survival of patients in the active treatment arm of 104 patients followed up to 8 years. Look out for a review from NYU of 32 RCT's being presented at MASCC and WALT later this year. We have a 8x centre NHS health economics study in progress too.

More news in two weeks with a review of research published in February, then every two weeks until we catch up and settle into a monthly stride.

  THOR Home THOR Blog About THOR Training Courses Products Contacts

THOR Photomedicine Ltd | Water Meadow House, Chesham, HP5 1LF, UK
THOR Photomedicine Inc | 5021 Michael's Meadow Drive, Hampstead MD 21074, USA
UK & rest of world +44 (0)1494 797 100 | USA +1 877 355 3151
Copyright 1993-2018 | All rights reserved. THOR Privacy Policy